Mitsubishi Tanabe Pharma Launches Albumin Injection
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma announced May 19 that it had initiated sales of Medway Injections, recombinant human serum albumin preparations that are jointly developed with Bipha Corp, a MTP subsidiary. Currently, albumin preparations are derived from human plasma. The new products use pichia pastoris as a host and utilize gene recombination technology to reduce contamination by infectious materials in the production process and to enable mass production. Bipha is the manufacturer and Benesis Corp, another MTP subsidiary will co-promote the products. Genetically modified albumin products are approved in the U.S. and Europe as additives to vaccines. (Click here for more - Japanese language)
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.